Previous 10 | Next 10 |
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Biohaven Ltd. (BHVN) is expected to report $-1.33 for Q3 2023
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® PR Newswire - Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscu...
2023-10-06 13:13:50 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven shares slide on pricing $225 million stock offering Biohaven proposes $...
2023-10-03 02:58:39 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven proposes $200M stock offering Biohaven stock jumps 33% in wake of BHV-1...
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commerc...
2023-10-02 16:42:42 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven stock jumps 33% in wake of BHV-1300 drug update Biohaven falls as FDA r...
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
2023-09-27 16:30:10 ET Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline ...
2023-09-27 13:48:39 ET Gainers: ShiftPixy ( PIXY ) +92% . SciSparc Ltd ( SPRC ) +42% . MSP Recovery ( LIFW ) +41% . Biohaven ( BHVN ) +28% . MillerKnoll ( MLKN ) +28% . American Strategic Investment Co ( NYC ) +22% . ...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...